|
Abstract To investigate the efficacy and safety of iron supplementation for treating pregnant women with thalassemia minor and iron deficiency during the third trimester of pregnancy. Methods：120 pregnant women who had diagnosed as thalassemia minor complicated with iron deficiency during the third trimester of pregnancy were selected as the research subjects from March 2018 to August 2020. According to the treatment will, these women were divided into group A, group B and group C (40 cases in each group). The women in group A was had not been treated by iron supplementation, the women in group B were treated by polysaccharide iron complex capsule, and the women in group C were treated by multidimensional iron oral solution. The changes of serum levels of serumferritin (SF), hemoglobin (Hb), Reticulocyte hemoglobin (RET-HE), and soluble transferrin receptor (sFr) of the women in the three groups before and after treatment were observed. Perinatal indexes and adverse pregnancy outcomes of the women in the three groups were also observed. Results：After treatment, the levels of SF, Hb, and RET-HE of the women in group B and C were significant higher than those before treatment, but the level of sTfR of the women in group B and C were significant lower than that before treatment (P＜0.05), and those of the women had no significant different between group B and group C (P＞0.05). The postpartum 24h blood loss of the women in group A was significant higher than that of the women in group B and C. The neonatal weight and 1 min Apgar score in group A were significant lower than those in group B and C (P＜0.05), and those had no significant between group B and group C (P＞0.05). The incidences of premature delivery, postpartum hemorrhage, abnormal amniotic fluid, and postpartum hemorrhagic shock of the women, and the rate of low body weight of fullterm newborns in group A were significant higher than those in group B and group C (P＜0.05), but the incidence of puerperal infection of the women had no significant among the three groups (P＞0.05). Conclusion: Oral iron supplementation can effectively improve the symptoms of iron deficiency and anemia of the pregnant women with thalassemia minor and iron deficiency during the third trimester of pregnancy, which will help to reduce the risk of adverse pregnancy outcomes, with better clinical effects and safety.
|
|
|
|
|
|
